Net sales surged 162% year-over-year to SEK 57.5M in H1 2025, driven by FDA approval and a $2M milestone payment for OTS Hip. Strong cash position and high equity ratio support ongoing international expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.